Overview

ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of ESPRIT was to compare the efficacy and safety of mild anticoagulation or a combination treatment of aspirin and dipyridamole with the efficacy and safety of treatment with aspirin alone after cerebral ischemia of arterial origin.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
UMC Utrecht
Treatments:
Aspirin
Dipyridamole
Criteria
Inclusion Criteria:

- Patients presenting in the participating hospitals with a TIA or non-disabling stroke
of atherosclerotic origin

- Randomisation within 6 months after the TIA or minor stroke

- Modified Rankin scale of 3 or less

Exclusion Criteria:

- (Contra)indication to, or intolerance to, anticoagulants, dipyridamole, or aspirin

- Disease expected to cause death within weeks or months

- Source of embolism in the heart

- Moderate or severe ischemic damage to the white matter of the brain (leukoaraiosis)

- Anemia, polycythemia, thrombocytosis, or thrombocytopenia

- Planned carotid endarterectomy

- Intracranial bleeding or cerebral tumour

- TIA or stroke caused by vasculitis, migraine, or dissection

- Severe hypertension

- Liver failure

- Pregnancy

- Chronic alcohol abuse